Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
For the treatment of anemia (from renal transplants or certain HIV treatment)
Tokai region, Aichi, Japan
Kanto region, Tochigi, Saitama, Tokyo, Kanagawa, Japan
Hokuriku region, Niigata, Ishikawa, Japan
Research Site, York, United Kingdom
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Shikoku region, Ehime, Japan
Kyusyu region, Fukuoka, Kagoshima, Japan
Chugoku region, Hiroshima, Tottori, Japan
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.